Cargando…

Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion

BACKGROUND: Ductal carcinoma in situ with microinvasion (DCIS-Mi) generally has favorable prognosis, but the long-term outcomes of DCIS-Mi and the biologic evolution from ductal carcinoma in situ (DCIS), DCIS-Mi, to DCIS with T1a breast cancer (DCIS-T1a) has not been specified. The aim of our study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Yan, Wu, Jiayi, Wang, Wei, Fei, Xiaochun, Zong, Yu, Chen, Xiaosong, Huang, Ou, He, Jianrong, Chen, Weiguo, Li, Yafen, Shen, Kunwei, Zhu, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325434/ https://www.ncbi.nlm.nih.gov/pubmed/27577080 http://dx.doi.org/10.18632/oncotarget.11639

Ejemplares similares

Presence of CHD1L Over-Expression Is Associated with Aggressive Tumor Biology and Is a Novel Prognostic Biomarker for Patient Survival in Human Breast Cancer
por: Wu, Jiayi, et al.
Publicado: (2014)

Progesterone Receptor Status and Ki-67 Index May Predict Early Relapse in Luminal B/HER2 Negative Breast Cancer Patients: A Retrospective Study
por: Zong, Yu, et al.
Publicado: (2014)

Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample
por: Zhu, Siji, et al.
Publicado: (2019)

Changes of Tumor Infiltrating Lymphocytes after Core Needle Biopsy and the Prognostic Implications in Early Stage Breast Cancer: A Retrospective Study
por: Huang, Jiahui, et al.
Publicado: (2019)

A Novel Prognostic Scoring System Integrating Gene Expressions and Clinicopathological Characteristics to Predict Very Early Relapse in Node-Negative Estrogen Receptor-Positive/HER2-Negative Breast Cancer
por: Lin, Caijin, et al.
Publicado: (2020)

Association of Molecular Biomarker Heterogeneity With Treatment Pattern and Disease Outcomes in Multifocal or Multicentric Breast Cancer
por: Li, Shuai, et al.
Publicado: (2022)

Clinical and imaging characteristics of breast ductal carcinoma in situ with microinvasion
por: Han, Sijia, et al.
Publicado: (2020)

Different distribution of breast ductal carcinoma in situ, ductal carcinoma in situ with microinvasion, and invasion breast cancer
por: Wei, Zhang, et al.
Publicado: (2012)

HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab
por: Li, Shuai, et al.
Publicado: (2020)

Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients
por: Li, Shuai, et al.
Publicado: (2021)

Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion
por: Okumura, Yasuhiro, et al.
Publicado: (2008)

Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26–30
por: Yu, Jing, et al.
Publicado: (2020)

Early response and pathological complete remission in Breast Cancer with different molecular subtypes: a retrospective single center analysis
por: Hong, Jin, et al.
Publicado: (2020)

21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes
por: Tong, Yiwei, et al.
Publicado: (2019)

IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients
por: Tong, Yiwei, et al.
Publicado: (2020)

Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?
por: Yu, Jing, et al.
Publicado: (2020)

A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age
por: Yu, Jing, et al.
Publicado: (2021)

Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients
por: Chen, Xiaosong, et al.
Publicado: (2015)

Molecular Subtype May Be More Associated With Prognosis and Chemotherapy Benefit Than Tumor Size in T1N0 Breast Cancer Patients: An Analysis of 2,168 Patients for Possible De-Escalation Treatment
por: Zhu, Siji, et al.
Publicado: (2021)

A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab
por: Hong, Jin, et al.
Publicado: (2019)

Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients
por: Lu, Yujie, et al.
Publicado: (2020)

Prognostic and predictive value of Ki-67 in triple-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2016)

Comparison of breast ductal carcinoma in situ and ductal carcinoma in situ with microinvasion, and analysis of axillary lymph node metastasis
por: Zhang, Geng, et al.
Publicado: (2020)

Diagnostic pitfall in a case of ductal carcinoma—in situ with microinvasion
por: Momin, Yasmin A, et al.
Publicado: (2016)

More microinvasive foci in larger tumours of breast ductal carcinoma in situ
por: Chen, Xiao-Yang, et al.
Publicado: (2022)

Biomarkers of Insulin and the Insulin-Like Growth Factor Axis in Relation to Breast Cancer Risk in Chinese Women
por: Zhu, Yifei, et al.
Publicado: (2020)

Associations Between Circulating Insulin-Like Growth Factor 1 and Mortality in Women With Invasive Breast Cancer
por: Zhu, Yifei, et al.
Publicado: (2020)

Factors Influencing Adjuvant Chemotherapy and Trastuzumab Choice in Older Human Epidermal Growth Factor Receptor 2-positive Breast Cancer Patients
por: Fang, Yan, et al.
Publicado: (2020)

Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center Study
por: Wu, Jiayi, et al.
Publicado: (2020)

Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy
por: Huang, Renhong, et al.
Publicado: (2023)

Impact of clinicopathological factors on extended endocrine therapy decision making in estrogen receptor–positive breast cancer
por: Chen, Weilin, et al.
Publicado: (2023)

Characteristics, prognosis, risk factors, and management of recently diagnosed ductal carcinoma in situ with microinvasion
por: Li, Chunyan, et al.
Publicado: (2021)

Comprehensive Association Analysis of 21-Gene Recurrence Score and Obesity in Chinese Breast Cancer Patients
por: Tong, Yiwei, et al.
Publicado: (2021)

Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component
por: Zeng, Yufei, et al.
Publicado: (2020)

A senescence-associated signature refines the classification of different modification patterns and characterization of tumor immune microenvironment infiltration in triple-negative breast cancer
por: Huang, Renhong, et al.
Publicado: (2023)

Targeting glutamine metabolic reprogramming of SLC7A5 enhances the efficacy of anti-PD-1 in triple-negative breast cancer
por: Huang, Renhong, et al.
Publicado: (2023)

Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients
por: Wu, Jiayi, et al.
Publicado: (2017)

Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study
por: Wang, Wei, et al.
Publicado: (2018)

Clinical characteristics of breast ductal carcinoma in situ with microinvasion: a narrative review
por: Zheng, Jie, et al.
Publicado: (2020)

Prognostic significance of microinvasion with ductal carcinoma in situ of the breast: a meta-analysis
por: Shiino, Sho, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3a4gk8srq06qus52phf18omn19